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Background: Non-fibrillar oligomers are implicated as neurotoxic species in several amyloid neurodegenerative diseases.
Results: Full-length prion protein (PrP) forms distinct non-fibrillar -sheet-rich oligomers. Truncated protein, lacking the N
terminus forms nonspecific aggregates.
Conclusion: The unstructured N terminus of PrP is key to the folding and aggregation of its structured region.
Significance: To examine the full repertoire of PrP conformers and assembly states, full-length protein should be used.
The self-association of prion protein (PrP) is a critical step in
thepathologyof priondiseases. It is increasingly recognized that
small non-fibrillar-sheet-rich oligomers of PrPmay be of cru-
cial importance in the prion disease process. Here, we charac-
terize the structure of awell defined-sheet-rich oligomer, con-
taining12 PrPmolecules, and often enclosing a central cavity,
formed using full-length recombinant PrP. The N-terminal
region of prion protein (residues 23–90) is required for the for-
mation of this distinct oligomer; a truncated form comprising
residues 91–231 forms a broad distribution of aggregated spe-
cies. No infectivity or toxicity was found using cell and animal
model systems.This studydemonstrates that examinationof the
full repertoire of conformers and assembly states that can be
accessed by PrP under specific experimental conditions should
ideally be done using the full-length protein.
Prion diseases are a group of fatal neurodegenerative diseases
that include bovine spongiform encephalopathy in cattle,
scrapie in sheep and goats, and Creutzfeldt-Jakob disease, Ger-
stmann-Stra¨ussler-Scheinker disease, fatal familial insomnia,
and kuru in humans (1).
According to the “protein-only” hypothesis, the key molecu-
lar event in the pathogenesis of these diseases is the conversion
of the host-encoded prion protein (PrP)8 from its normal cellu-
lar conformation (PrPC) to disease-associated isoforms often
referred to as PrPSc, which may form amyloid deposits.
Although the precise molecular events involved in this conver-
sion and the precise structure of infectious prions remain ill-
defined, molecular genetic and in vitro studies suggest that
PrPSc acts as a template that promotes the conversion of PrPC to
PrPSc and that the difference between the two isoforms lies
purely in the monomer conformation and its state of aggrega-
tion (1, 2).
PrPSc is classically defined in terms of its detergent insolubil-
ity and relative protease resistance and has a high -sheet con-
tent (3–5). In contrast, PrPC consists of a predominantly -hel-
ical structured domain and an N-terminal segment, which is
unstructured in solution conditions, with a single disulfide
bond forming an integral part of the core of the C-terminal
structured domain (6–8).
Although it is clear that prion pathology is generally associ-
ated with PrP aggregation and the deposition of abnormal pro-
tein deposits, it is increasingly recognized that there are multi-
ple disease-related forms of PrP, including protease-sensitive
species, which might comprise the majority of infectivity in
some isolates (9–11). In particular, small non-fibrillar -sheet-
rich oligomers have been suggested to be the most efficient
mediators of prion infectivity (12), and have been shown to
exhibit more neurotoxicity both in vitro and in vivo than the
fibrillar forms of PrPSc (13). Small oligomeric species have also
been implicated in other amyloid-related diseases (14–20) and
may provide targets for diagnostic and therapeutic treatment.
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Several non-fibrillar oligomers have been obtained through
the in vitro misfolding of PrP (13, 21–31), ranging in size
(10–50 nm diameter) and in the minimum number of mono-
mer subunits required (8–10monomers) to form the oligomer.
Generally these oligomers are rather aggregation prone and
appear as transient species during the conversion to larger
fibrils. The transient nature of these small oligomers has made
it difficult to study their properties, structure, and relationship
to fibrils and their physiological role (16). Whether such olig-
omers represent on- or off-pathway intermediates to amyloid
formation remains contentious, however many of them display
increased -sheet structure and resistance to proteolysis,
despite being soluble under physiological conditions (13, 22, 23,
26, 32, 33).
One such PrP species, termed -PrP, is formed when PrP is
refolded at acidic pH in a reduced state, with the disulfide bond
broken (28, 34). This form of the protein assembles into soluble
oligomers that have significant -sheet content and partial
resistance to proteinase K digestion, both properties character-
istic of PrPSc, and also forms amyloid fibrils which closely
resemble those isolated from diseased brains (34, 35). In addi-
tion, -PrP is antigenically distinct from native PrPC and inhib-
its proteasome activity at nanomolar concentrations, a mecha-
nism by which PrPSc has been proposed to effect neuronal
death (36–38). Preincubation of -PrP with an antibody spe-
cific for oligomerized proteins relieves this inhibition, consis-
tent with oligomeric species mediating this effect (37). These
data suggest amechanism for intracellular toxicitymediated by
defined oligomers ofmisfolded prion protein.-PrP-associated
inhibition of proteasome activity is most potent when full-
length PrP (residues 23–231) is refolded to the -PrP confor-
mation (-PrP23–231), rather than the shortened PrP molecule
comprising residues 91–231 (-PrP91–231). This suggests that
PrP is capable of adopting distinct conformational isoforms
that are dependent on the length of its polypeptide chain. To
resolve this and also to clarify its relationship to PrPSc, we have
characterized the physical and biological properties of full-
length -PrP23–231, in particular its structural organization and
potential toxicity and infectivity. We demonstrate that the
intrinsically unstructuredN-terminal region of the protein is of
crucial importance in the intermolecular association and fold-
ing of the disulfide-reduced form of prion protein.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Preparation—Recom-
binant mouse PrP proteins were prepared and purified as pre-
viously described, including the preparation of labeled (15N and
13C/15N) protein for NMR studies (39). The purification of full-
length PrP23–231 (PrP residues 23–231) differed slightly from
that of PrP91–231 (PrP residues 91–231) in that following the
initial nickel-nitriloacetic acid purification step and cleavage of
the His tag, the final purification step involved reapplication of
the protein to a second nickel-nitriloacetic acid column equili-
brated in 20 mM BisTris, 25 mM imidazole, pH 6.5, and elution
with 1 M imidazole in the same buffer.
Protein samples were converted from the normal -helical
conformation (-PrP) to the -sheet conformation (-PrP), by
reducing the protein disulfide bond and refolding at acidic pH
as previously described (28, 34). Briefly, this was performed by
denaturation of PrP in 6 M GdnHCl in the presence of 100 mM
DTT to a final concentration of no more than 1 mg/ml, and
subsequent refolding by dialysis against 10 mM sodium acetate,
2mMDTT, pH4.-PrP91–231 sampleswere subject to ultracen-
trifugation at 150,000 g for 4 h.-PrP23–231 samples were not
subjected to a similar ultracentrifugation step after establishing
that the yield, CD spectrum, and sedimentation coefficient dis-
tribution of the -PrP23–231 preparations were not affected by
the centrifugation procedure. -PrP23–231 was assembled into
fibrils by treating 0.27 mg/ml of -PrP23–231 in 10 mM sodium
acetate, pH 4.0, with 1/9 volume of a 5 M stock of GdnHCl or
NaCl (in the same buffer) to give final protein and denaturant
concentrations of 0.25 mg/ml and 0.5 M, respectively.
CD Spectroscopy—Far UV CD spectra were acquired on a
JASCO J-715 spectropolarimeter using typically 0.1-mm path
length cuvettes and 10 accumulations, 1 nm bandwidth, 1 s1
integration. Near UV CD spectra were typically acquired using
2-mm path length cuvettes and 30 accumulations. -PrP spec-
tra were acquired in 10 mM sodium acetate, 2 mM DTT, pH 4,
-PrP in 20 mM BisTris, pH 6.5. Mean residue ellipticity was
calculated as []R deg cm2 dmol1 res1.
NMR Spectroscopy—NMR spectra were acquired at 298 K on
Bruker DRX-600 and DRX-800 spectrometers equipped with
5-mm 13C/15N/1H triple-resonance probes on -PrP23–231
samples ranging in concentrations up to 8 mg/ml (330 M).
Backbone resonance assignments of-PrP23–231 were achieved
using the standard suite of triple resonance experiments
(HNCO, HN(CA)CO, HNCACB, and CBCA(CO)NH) (40–
43). Proton chemical shifts were referenced to 1 mM sodium
3-trimethylsilyl-2,2,3,3-(2H4)propionate added to the samples.
15N and 13C chemical shifts were calculated relative to sodium
3-trimethylsilyl-2,2,3,3-(2H4)propionate, using the gyromag-
netic ratios of 15N, 13C, and 1H (15N/1H  0.101329118, 13C/
1H 0.25144953). NMR data were processed and analyzed on
Linux Workstations using Felix 2007 (Accelrys, San Diego)
software. The backbone assignment was performed using the
asstools set of assignment programs (44).
Analytical Ultracentrifugation—Sedimentation velocity
ultracentrifugation experiments (SV-AUC) were carried out
using a Beckman Optima XL-I analytical ultracentrifuge. Sam-
ples were loaded into Beckman AUC sample cells with 12-mm
optical path two-channel centerpieces, with matched buffer in
the reference sector. Cells were spun at 50,000 rpm in an
AnTi-50 rotor, and scanswere acquired using both interference
and absorbance optics (at 280 nm) at 10-min intervals over 16 h.
The sedimentation profiles were analyzed using the software
SEDFIT (v13b) (45). Partial specific volumes for mouse
PrP91–231 and PrP23–231 were calculated from the amino acid
sequence using SEDNTERP software (46). Buffer densities and
viscosities weremeasured using an Anton Paar DMA5000 den-
sity meter and an Anton Paar AMVn automated microviscom-
eter, respectively. Sedimentation velocity data were analyzed
using the c(s) method of distribution (45) to characterize the
sedimentation coefficient distribution of all species present in
solution. For the -PrP samples, it was necessary to use a
bimodal f/f0 fit, to separately fit the frictional ratios for mono-
mer and larger species. The proportions of each sample occu-
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pying the main peaks in the distribution were calculated by
integration of the peaks.
Asymmetric Flow Field-Flow Fractionation—Asymmetric
flow field-flow fractionation (AF4) experiments were per-
formed using theWyatt Eclipse 3with delay-corrected inline
monitoring of UV (275 nm), refractive index, and light scatter-
ing coupled to an Agilent Affinity 1200 HPLC. A short channel
(145 mm length) containing a 350-m trapezoidal spacer and
5-kDamolecular mass cut-off polyethersulfone membrane was
used for separation. Sampleswere run in 10mM sodiumacetate,
2 mMDTT, pH 4. Typically, injections of 50 l were performed
with a cross-flow of 1.5 ml/min over 1 min followed by 1 min
focusing time, and elution with 1.5ml/min cross-flow.Weight-
averagedmolarmass (Mw), and hydrodynamic radius were cal-
culated, where possible, from the data using ASTRA6 software.
UreaDenaturation—Samples for simultaneousCDandAUC
analysis were prepared in various concentrations of urea (0.0–
6.0 M) in 10 mM sodium acetate, 2 mMDTT, pH 4.0, by dilution
of the -PrP23–231 stock solution with 9 M urea in the same
buffer as appropriate. Samples were then concentrated to 50
MPrP usingVivaspin 6 spin concentrators (Sartorius), and the
flow-through used as the matched buffer reference for CD and
AUC experiments.
Equilibrium Denaturation Data Analysis—The amide (far
UV) CD absorption of 50 M -PrP23–231 in 10 mM sodium
acetate, 2 mMDTT, pH 4.0, was recorded in varying concentra-
tions of urea as described above. The mean residue ellipticity
signal ([]r) at 215 nmwas converted to the proportion of mol-
ecules in the unfolded state, U, according to the relationship
U  1  [(([]ri  []r5M)/([]r0M  []r5M))  100], where
[]r0M and []r5M are the mean residue ellipticity values for the
beginning and end of the urea denaturation transition (i.e. 0 and
100%, respectively). The normalized data were then fitted to a
two-state unfolding equation,
U  KN/U  expm  D/1 KN/U  expm  D (Eq. 1)
wherem represents the sensitivity of the unfolding transition to
denaturant andD is the denaturant concentration (47). For the
AUC data, the integrated value for percentage occupancy of
monomer peakwas used forU and this was used directly in the
equation.
The two-state unfoldingmodel is not formally correct for the
observed -PrP23–231 unfolding transition, as the data repre-
sent a transition between monomeric species at high urea con-
centration and oligomeric species at lower urea concentrations.
The form of the CD transition does nevertheless follow that for
two-state unfolding and therefore the data were fitted to the
two-state unfolding model to derive minimum and maximum
values for []r, representing the signal of folded and unfolded
species, regardless of association state. These values were then
used to derive the proportion of folded species at each urea
concentration.
Determination of Protease Resistance—-PrP23–231 and
-PrP23–231 at pH 6.0 were digested with varying concentra-
tions (0.005–50 g/ml) of proteinase K (PK; British Drug
Houses) at 37 °C for 1 h and diluted to 1 mg/ml in 10 mM
sodium acetate, 10 mM Tris acetate, pH 6.0. Digestion was ter-
minated by the addition of Complete ULTRA Protease Inhibi-
tor (Roche Applied Science). Samples were heated to 100 °C for
5 min in SDS loading buffer before electrophoresis on 16% Tris
glycine polyacrylamide gels (Novex). Gels were Coomassie
stained.
Negative Stain Electron Microscopy—300-Mesh carbon-
coated grids (Electron Microscopy Sciences) were glow dis-
charged for 40 s (to make them hydrophilic) using an EMS
100 glow discharge unit (Electron Microscopy Sciences)
immediately before loading the sample. 5 l of protein at a
concentration of 0.5mg/ml was allowed to bind for 2min, grids
were blotted with grade 4 Whatman filter paper, washed twice
briefly with water, then stained with 2% (w/v) uranyl acetate
(Agar Scientific) for 45 s. Excess stain was then removed by
blotting and gridswere allowed to air dry. As a precaution, grids
were loadedwithin a class 1microbiological safety cabinet in an
ACDP level III containment laboratory. Grids were analyzed
using an FEI Tecnai T12 Transmission Electron Microscope
(FEI, Eindhoven, NL) at an accelerating voltage of 120 kV using
a dedicated sample holder for potentially infectious material
and handled using appropriate safety measures. After use, the
holder was decontaminated using a Plasma Cleaner (Fischione
Instruments).
Electron Tomography—Samples were prepared in the same
manner as for negative stain electron microscopy. Serial EM
(48) was used to acquire a single axis tilt series with a tilt range
of	 60° with 2° increments. Digital imageswere recorded using
a 1K 61K GatanMultiscan 794 CCD camera at a nominal mag-
nification of 42,000 with a pixel size of 4.1 Å and a typical defo-
cus of 1.2 m. IMOD version 4.3 (49) was used to reconstruct
tomograms from the tilt series using local patch tracking for
alignment.
PrP Molecular Volume Calculation—To derive estimates of
the number of monomers per oligomer for the EM data for
which particle dimensions were measured, two different meth-
ods to estimate themolecular volume of recombinant PrP23–231
were used. A molecular volume of 27.5 nm3 was calculated
using molecular weight and the calculated partial specific vol-
ume of 0.7078 cm3/g. Molecular volume was also estimated
using the program Vossvolvox (50). A modeled Protein Data
Bank file of full-length PrP, comprising residues 23–231 but
lacking the GPI anchor and carbohydrate moieties was used as
input, giving a volume estimate of 30 nm3, in close agreement
with the estimate using partial specific volume.
Cell Viability Experiments—N2a mouse neuroblastoma cells
(subclone PK1) (51) chronically infected with RML prions or
uninfected were cultured in OptiMEM (Invitrogen) supple-
mented with 10% FCS (Invitrogen) and 1% penicillin/strepto-
mycin (Invitrogen). Cells were seeded in a 384-well plate at
6000 cells per well. Preparations of -PrP23–231 at 6 mg/ml,
-PrP23–231 at 4.6mg/ml, and fibrillar-PrP23–231 (prepared as
described above) in 10 mM sodium acetate, pH 4, and a buffer
control were assessed for cytotoxicity. For each sample, a
10-fold dilution into cell media wasmade and then serial 3-fold
dilutions were prepared. n 3 wells were exposed to each con-
centration of PrP and buffer for 3 days prior to performing the
CellTiter-Glo luminescent cell viability assay (Promega), which
measures total viable cell number by quantification of ATP in
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whole cell lysates. Untreated cells were used as negative
controls.
In Vivo Infectivity Experiments—30 l of -PrP23–231 at 1
mg/ml was injected into the right parietal lobes of 10 recipient
CD1 mice at the age of 4–6 weeks. 10 CD1 mice were inocu-
lated with the corresponding preparation buffer as negative
controls. Mice were monitored for signs of scrapie infection
throughout their normal lifetime, culled according to Home
Office guidelines, and their brains taken for neuropathological
examination using immunohistochemistry and Western blot-
ting. Brain sections were checked for spongiform neurodegen-
eration using Harris hematoxylin and eosin staining, the prolif-
eration of reactive astrocytes using anti-GFAP antibodies, and
abnormal PrP immunoreactivity using the anti-PrP monoclo-
nal antibody ICSM-35 (D-Gen Ltd., London) (52). Appropriate
positive and negative controls were used throughout.
RESULTS
-PrP23–231 Is Characterized by -Sheet Structure and a
Low Degree of Tertiary Organization—Both -PrP23–231 and
-PrP91–231 display far-UV CD spectra characteristic of sec-
ondary structures dominated by a -sheet, with a single mini-
mum close to the characteristic -sheet minimum at 215 nm
(Fig. 1A) (53). The CD spectra are similar to those observed for
a number of oligomeric and amyloid-like PrP species (54–56)
and are in marked contrast to the equivalent spectra of native
full-length mouse -PrP23–231. The latter show a minimum at
208 nm and a shoulder at 222 nm, characteristic of a protein
dominated by the -helical secondary structure (Fig. 1A). The
nearUV (aromatic) CD spectrumof-PrP23–231 displaysmark-
edly reduced intensity in comparison with that of natively
folded-PrP, indicating that the protein side chains of aromatic
residues within -PrP23–231 are in less asymmetric environ-
ments than in the natively folded protein (Fig. 1B).
-PrP23–231 Populates a Discrete Oligomeric Species—The
significant -sheet content and reduced level of tertiary struc-
ture for -PrP23–231 are features shared with -PrP91–231. This
truncated form of PrP was previously determined to be pre-
dominantly oligomerized under native conditions (28). We
thus sought to confirmwhether-PrP23–231 was similarly com-
posed primarily of oligomeric species. Intriguingly, despite dis-
playing very similar CD spectra, the two -PrP species,
-PrP91–231 and -PrP23–231, were found to oligomerize in rad-
ically different manners; the former forming a broad range of
soluble oligomeric species, and the latter forming a defined,
distinct oligomeric state. This was shown initially using SV-
AUC (Fig. 2A). Analysis at 1.0 mg/ml showed that -PrP23–231
is comprised of two discrete species with sedimentation coeffi-
cients of 1.5 	 0.1 and 5.6 	 0.6 S, characterized by frictional
ratios of 1.8	 0.3 and 3.0	 0.5, respectively, giving molecular
masses of 23 	 3 and 280 	 42 kDa. These molecular masses
correspond with those of the monomer and of an oligomer
comprising12	 2 monomer subunits. This is markedly dif-
ferent to -PrP91–231, which does not populate any dominant
species larger than the monomer, but rather populates a broad
distribution of oligomeric species sedimenting between 2 and
30 S, with estimated molecular masses up to 2 MDa (Fig. 2A)
(28). By way of comparison, PrP23–231 and PrP91–231 refolded
into the native -PrP conformation each show a single species
sedimenting at 2 and 1.7 S, with frictional ratios of 1.6 and 1.5,
respectively. These values translate to molecular masses of 23
and 17 kDa, which match closely the expected molecular
masses for the monomeric species (Fig. 2B).
The oligomeric species in the samples (both the discrete
-PrP23–231 oligomer and the broad distribution -PrP91–231
oligomers) are characterized by large frictional ratios f/f0 3.0 for
-PrP23–231 and f/f0 3.6 for -PrP91–231), indicating signifi-
cantly non-spherical character for both oligomers. This con-
trasts with the -PrPmonomers, which display lower frictional
ratios, consistent with the slightly elongated structured core
region (residues 121–231), connected to an unstructured
N-terminal tail of 100 or 30 residues (6, 39). For both full-length
and truncated PrP, the -PrP monomers are characterized by
slightly larger frictional ratios (1.8) than the -PrP monomers,
which results in their slightly slower sedimentation and smaller
sedimentation coefficient (Fig. 2B). This is consistent with a
slightly less compactmonomeric state resulting from the loss of
conformational restriction imposed by the native disulfide
bond (7, 8).
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FIGURE 1. Secondary and tertiary structure organization of -PrP,
-PrP91–231, and -PrP23–231. A, far-UV CD spectra. Both -PrP species
(-PrP23–231,dotted line;-PrP91–231,dashed line) displayCD spectra indicative
of secondary structure dominated by -sheet, in contrast with -PrP23–231
(solid line), which exhibits characteristic -helical double minima at 208 and
222 nm. B, near-UV CD spectra. Natively folded-PrP displays strong near-UV
CD signals (solid line), indicating that the side chains of its aromatic residues
are in asymmetric environments characteristic of fully folded, globular pro-
teins, and it has a well defined tertiary structure. The near-UV CD signal of
both-PrP species (-PrP23–231, dotted line;-PrP91–231, dashed line) aremark-
edly reduced in comparison, consistent with a partly folded intermediate
conformation lacking extensive well defined tertiary contacts. The data are
representative of 6 repeats of the standard CD acquisition.
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The presence in solution of the -PrP23–231 monomer and a
distinct, well defined -PrP23–231 oligomeric species was con-
firmed by asymmetric-flow field-flow fractionation (AF4), a
technique that has previously been used to separate small non-
fibrillar -sheet-rich oligomers of PrP from scrapie-infected
mouse brain material (12). The molecular mass determined for
the oligomer using this technique was 226 	 36 kDa, in
agreement with the values obtained using AUC (Fig. 3), and the
number of monomers in infectious prion particles (12). The
monomeric species was similarly identified with a close corre-
spondence with the AUC data (Fig. 3). The hydrodynamic
radius of the oligomer was determined using in-line dynamic
light scattering measurements to be11 nm. Notably, the AF4
data indicated a low degree of polydispersity for the oligomeric
species (1.04), indicating that the -PrP23–231 oligomer was
highly homogeneous.
-PrP23–231 -Sheet Structure Is Associated with its Olig-
omerization—The relative proportions of the -PrP23–231
monomer and oligomer could be readily changed by altering
the protein concentration. The proportion of the -PrP23–231
oligomeric species was found to increase from 24% to greater
than 50% by elevating the -PrP23–231 concentration from 0.44
to 5 mg/ml. When the protein was incubated at 5 mg/ml and
then diluted back to 0.44 mg/ml this elevated oligomer/mono-
mer ratio was retained comparedwith a sample refolded at 0.44
mg/ml (Fig. 4A), which indicates that the rate of equilibration
between the oligomer andmonomer is slow on the timescale of
measurement (hours). Increasing the proportion of -PrP23–231
oligomer was found to alter the observed far-UV CD response.
The far-UV CD spectrum of a 0.44 mg/ml sample that had not
been concentrated displayed a minimum at 208 nm, consis-
tent with a mixed population of predominantly random coil
and predominantly -sheet conformers (Fig. 4B), whereas the
spectrum of a 0.44 mg/ml sample that had been previously
incubated at 5 mg/ml displayed a minimum at 213 nm indi-
cating a shift in population in favor of -sheet-rich conformers.
This indicates that the primary -sheet CD response is derived
from the oligomers. These spectra also reflect that the mono-
meric form of -PrP23–231 folds into a conformation that is
characterized by a major loss of -helical structure and
increased proportion of unordered structure, and is qualita-
tively similar to the behavior of the monomeric form of
-PrP91–231 (57). The strong correlation between the -sheet
far-UV CD response and the aggregation state of -PrP23–231
was further established through the equilibrium denaturation
of -PrP23–231 (Fig. 5). Comparison of the proportion of olig-
omeric species determined using AUC with the CD signal at
215 nm indicated that the denaturant-dependent loss of
-sheet CD signal coincided with the reduction of the oligomer
population (and concomitant increase in the proportion of
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monomers) (Fig. 5B). The oligomeric species was found to
unfold in a smooth transition with a low dependence on dena-
turant (Fig. 5B), indicating that the -oligomeric species is not
associated with a large scale burial of hydrophobic groups.
-PrP23–231 Oligomer Structure—The structural organiza-
tion of the-PrP23–231 oligomers was characterized by electron
tomography (Fig. 6). Oligomers were examined by negative
stain EMand reconstructed by electron tomography. The latter
reveals distinct particles with a diameter of 8.4 	 1 nm and a
height of 9 	 1.3 nm, which can associate to form extended
structures composed of 2–3 oligomers. This higher-order asso-
ciation of oligomers may explain the extended frictional ratios
required to describe the 5 S species identified using AUC (Fig.
2). In addition, a central cavity of 2.8	 0.7 nm diameter (Fig. 6)
is observed in many of the oligomers, similar to oligomers cap-
tured along the assembly and disassembly pathways of tran-
sthyretin amyloid protofibrils (58). The size of the particles
identified lies within the size estimates expected given the
molecular weight of the oligomers determined using AUC and
AF4. The size estimates for the -PrP23–231 oligomers (7–10
nm) and minimum assembly state (11–12 monomers) are thus
in keeping with other distinct non-fibrillar PrP oligomers that
have been reported (see “Discussion”).
NMR Characterization of -PrP23–231—As -PrP23–231 was
found to be soluble at high concentrations (8 mg/ml), its
structural properties on a per-residue basis could be examined
using solutionNMR (Fig. 7), in particular allowing the determi-
nation of the involvement of the N-terminal region in the dis-
tinct oligomeric species. Intriguingly, despite oligomerizing in a
radically different manner, the NMR spectrum of -PrP23–231
was found to be very similar to that of the truncated-PrP91–231
form. Both -PrP species give NMR spectra displaying mark-
edly reduced chemical shift dispersion of resonances in com-
parison with natively folded -PrP. The 1H NMR spectrum of
-PrP (Fig. 7) is characteristic of a fully folded globular protein,
with wide chemical shift dispersion, including a number of
upfield-shiftedmethyl peaks that are found at
0.7 ppm,which
are indicative of strong tertiary interactions between aromatic
residues and methyl side chains. In contrast, the NMR spectra
of the -PrP species are dominated by narrow clusters of
intense peaks, the majority of which lie within chemical shift
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ranges characteristic of random coil, unfolded peptides. As
found in -PrP91–231, and a number of other partially folded
and oligomeric PrP states (26, 28, 55, 59), these intense peaks
observed in the -PrP23–231 NMR spectra were assigned to res-
idues in the N terminus of the protein, residues 23–126. These
were found to have chemical shift values very similar to those
observed in the unstructured N terminus of -PrP and
-PrP91–231, consistent with this region of the protein remain-
ing predominantly unstructured in -PrP23–231.
The low near-UV CD signal and lack of chemical shift dis-
persion in the NMR spectra are indicative of little tertiary orga-
nization within -PrP23–231. However, the strong far-UV
response indicates a significant -sheet secondary structure
and thus -PrP23–231 behaves as a partly folded, molten globule
state (60). These folding intermediates are characterized by
near-native secondary structure, but little tertiary structure; the
fluctuating nature of this species often results in the exchange
broadening of NMR signals including their complete loss (61).
Indeed, the number of observable peaks in the NMR spectra of
-PrP23–231 was significantly fewer than expected, indicating
that there is a loss of signal through line broadening in the
-PrP23–231 monomer and oligomer. Thus given the lack of
tertiary interactions and its oligomerized state, the majority of
-PrP23–231 NMR resonances appear to be broadened due a
combination of molten globule intermediate exchange kinetics
and the relatively long rotational correlation time of the olig-
omeric species. It was not possible to differentiate signals aris-
ing from the monomeric and oligomeric species.
-PrP23–231 Is Resistant to Proteinase K Digestion—As
-PrP23–231 forms such a distinct oligomeric state, rather than
the broad distribution of large oligomers observed in -
PrP91–231, we wished to determine the relative PK resistance of
-PrP23–231 (Fig. 8). -PrP23–231 was highly resistant to PK
digestion, with undigested -PrP23–231 still observed after
digestion with 5 g/ml of PK (1 h at 37 °C). The degree of pro-
tease resistance of -PrP23–231 is of the same order as that
observed with -PrP91–231 (34), suggesting that resistance to
PK digestion in both -PrP conformers is likely to be primarily
due to the structural reorganization from -helical to -sheet
conformation rather than aggregation. In contrast, the pre-
dominantly -helical -PrP conformation was extremely sen-
sitive to digestion with PK, and was completely digested by the
addition of 0.05 g/ml of PK after 1 h at 37 °C (Fig. 8).
-PrP23–231 Forms Fibrils Under Increased Salt Concen-
trations—In common with -PrP91–231, titration of -PrP23–231
with thedenaturantGdnHClwas found to increase its intermolec-
ular association, and a conversion to oligomeric structures whose
morphologycouldbestudiedbyEM.Thisaggregationprocesswas
stimulated by equivalent concentrations of NaCl, indicating that
this process is primarily an effect of increased ionic strength. Elec-
tronmicrographs of-PrP23–231 in 0.5 MGdnHCl and 0.5 MNaCl
(Fig. 9) showed fibril-like structures with widths ranging from 10
and 16 nm, and variable lengths up to 2 m. In addition to these,
irregular amorphous aggregates of variable shape and size were
also observed.
-PrP23–231 Toxicity and Infectivity—We tested the effect of
-PrP23–231 on the viability of neuroblastoma cells (PK1) (51)
by serial dilutions of the preparation into the cell growthmedia.
No significant effect on cell viability was observed using an olig-
omeric -PrP preparation at concentrations ranging from
0.002 and 460 g/ml (Fig. 10). Fibrillar preparations of
-PrP23–231, and natively folded -PrP23–231 over similar con-
centration ranges also did not affect the PK1 cell viability. This
cell system thus provides no evidence for a toxic effectmediated
by the -PrP oligomers when applied externally.
The infectivity of -PrP23–231 was also investigated. 10 CD1
mice were observed for 600 days (close to natural lifespan) for
development of prion disease pathology following intracerebral
injection of-PrP23–231 (into the right parietal lobe). 10 control
FIGURE 6. -PrP23–231 oligomers imaged by electron tomography. A sec-
tion of a tomographic reconstruction of negatively stained -PrP23–231
reveals particleswith dimensions of8 9nm, and a central cavity or cleft of
3 nm diameter (solid square), which can associate into extended structures
(dotted square). Scale bar, 50 nm.
α-PrP
β-PrP91-231
β-PrP23-231
10 7 4 1
ppm
FIGURE 7. Representative one-dimensional 1H NMR spectra of -PrP,
-PrP91–231, and-PrP23–231.-PrP displays awell dispersedNMR spectrum
characteristic of a fully folded protein containing well defined tertiary struc-
ture. In contrast, signals observed in both -PrP species are restricted to res-
idues in the unstructuredN terminus of the protein (up to residue 126). This is
highlighted by the observed signals at10.2 ppm, which arise from trypto-
phan side chains and occur exclusively within the unstructured N terminus.
Signals from the remainder of the protein are broadened beyond detection
by a combination of exchange broadening from molten globule formation
and the high molecular weight soluble oligomeric species. At the protein
concentration used (8 mg/ml) the dominant species in the -PrP23–231 NMR
sample is the oligomer.
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CD1mice were inoculated with the corresponding -PrP23–231
preparation buffer. No mice developed clinical signs of murine
scrapie. The brains of all mice were removed for neuropatho-
logical examination andWestern blot analysis at the end of the
experiment to determine whether there was evidence of sub-
clinical prion infection. There was no prion neuropathology on
histological or immunocytochemical analysis and no PrPSc was
detected by Western blot analysis.
DISCUSSION
The molecular basis of prion neurotoxicity remains largely
unknown. Loss of PrPC function, as it is sequestered into aggre-
gated forms, is not a sufficient cause because its depletion does
not result in neurodegeneration (62, 63). It is increasingly rec-
ognized that multiple disease-related forms of PrP, other than
PrPSc, exist and may differentially contribute to prion infectiv-
ity or toxicity, which can be uncoupled (64). Interest has
focused on the role of small non-fibrillar -sheet-rich olig-
omers in prion and other amyloid diseases (12, 14, 16–19, 21,
32). In particular, it has been proposed that soluble oligomers
are common to most amyloidotic diseases and may represent
the primary toxic species (65). The distinct oligomer formed by
the reduced and acidified form of full-length recombinant PrP
is thus of interest as a candidate toxic or infectious species.
Here, we show that full-length recombinant prion protein,
comprising residues 23–231, can be refolded in vitro into a well
defined non-fibrillar -sheet-rich oligomeric form. These olig-
omers, formed in the folding of the full-length protein contrast
markedly with similar reduction and refolding of truncated PrP
residues 91–231. Our study provides a detailed structural char-
acterization of this previously uncharacterized PrP oligomeric
structure.
Electron tomograms show particles with dimensions8 9
nm, often containing a cavity or cleft. Using the monomer
molecular volume (see “Experimental Procedures”), and the
calculated volume of the TM particles (assuming an annular
structure), the number of PrP23–231 molecules per oligomer is
estimated to be 16 	 5. Given the assumption that the entire
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FIGURE 8. Protease K resistance and cleavage patterns of full-length
-PrP23–231 (A) and-PrP23–231 (B).Protein sampleswere incubated at vary-
ing concentrations of proteinase K (0–50 g/ml) in buffer at pH 6 and then
analyzed by SDS-PAGE. -PrP23–231 exhibited partial resistance to PK diges-
tion,with undigestedprotein persisting at 5g/ml of PK,whereas-PrP23–231
is fully digested at 0.05g/ml of PK. Novex SeeBlue Plus2 Molecular weight
markers are shown on the left of each gel. FIGURE 9. Assembly of -PrP23–231 into fibrils. -PrP23–231 is capable of
associating into long unbranched fibrils, with diameters of up to 16 nm and
lengths of several microns through the addition of 0.5 M GdnHCl (A) or 0.5 M
NaCl (B). Both of these images are of -PrP23–231 following 24 h incubation in
either GdnHCl or NaCl, respectively. The scale bar in the images corresponds
to 200 nm.
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volume of the particle is occupied by PrP molecules, the true
oligomer number is likely to be smaller, making this value
broadly consistent with the molecular mass estimates deter-
mined by the solution methods AF4 and AUC, which indicate
12 PrP23–231molecules per oligomer (280 kDa). These solu-
tion methods have a major advantage over size exclusion chro-
matography, typically used to characterize oligomeric species
and protein association states, in that they can be used to ana-
lyze samples at very low ionic strength. The structure of the
oligomer is similar to that identified for oligomers captured
along the assembly and disassembly pathways of transthyretin
amyloid protofibrils (58).
Both the distinct -PrP23–231 oligomer and the aggregated
species formed by -PrP91–231 share similar far-UVCD spectra
indicating a dominance of -sheet structure. The formation of
-sheet structure for both proteins is concomitant with their
oligomerization; the monomeric states exhibiting little defined
secondary structure and therefore relatively silent by CD spec-
troscopy. For both CD and NMR the size of the species cannot
be determined from their respective signals, and neither can the
monomer and oligomer be differentiated. The complementary
solution methods used here have proved necessary to enable
the protein association state to be verified independently of the
spectroscopic signal. The volume and size measurements indi-
cated by these different techniques are similar to a number of
other discrete non-fibrillar oligomers formed from recombi-
nant PrP under various in vitro folding conditions (13, 21,
23–27, 29–32, 66).
Although -PrP is recognized differentially by the host
immune system (36) and antibodies raised against it immuno-
precipitate disease-associated PrPSc (but not native PrPC) the
oligomeric preparation used in this study was not found be
infectious, nor to affect PK1 cell viability, when applied
externally.
The oligomers characterized here are broadly similar in olig-
omeric size and -sheet structure to those identified as the
most infectious particles from scrapie-infected mouse brain
material (12). However, the generation of high titer prions from
recombinant PrP remains contentious (64, 67, 68), with studies
often indicating a requirement of polyanions and/or other
brain-derived material for infectivity (68, 69). Confirmation of
whether-PrP23–231 requires interactionwith an as yet uniden-
tified co-factor for infectivity remains to be determined. It has
been proposed that PrP-lipid charge interactions are required
as a first step in the conversion of PrPC to PrPSc, consistent with
this conformational transition occurring in lipid raft domains
(70, 71), and membrane-like conditions are involved in the for-
mation of a similarly sized oligomeric PrP intermediate (21, 32).
The precise subcellular localization of PrPSc propagation, how-
ever, remains ill-defined, and late endosome-like organelles or
lysosomeswith acidic pH are, however, also implicated (72, 73).
Although we do not observe a specific cellular toxicity of this
-PrP23–231 preparation, several recombinant -oligomers are
reported to be toxic to neuronal cell cultures (13, 29, 30, 66, 74,
75). The variety of cell types tested, the various preparations of
recombinant PrP oligomers, and the considerable experimental
variation may explain variability in toxicity, but it is also prob-
able that subtle differences between the various species under
investigation can result in large differences in biological effect.
Indeed this has been reported for the bacterial proteinHypF-N;
this protein forms two oligomers that are similar according to
AFM and thioflavin T reactivity, but toxicity is displayed by the
one that is characterized by a lower degree of hydrophobic
packing (76). The reducing/acidic conditions for the -PrP
oligomerization may be unfavorable for the production of tox-
ic/infectious oligomers, however, it is also possible that -PrP
toxicitymay occur via amore discretemechanism, or biological
activity requiring perhaps other specific binding partners (for
example, the PrP/A interaction) (77), in which only certain
transient A assemblies cause PrP-dependent toxicity (20), and
thus may require the application of the oligomer to more spe-
cialized models.
Notably, formation of this distinct oligomer requires resi-
dues 23–90. This region intriguingly remains unstructured and
not directly incorporated into the -sheet-rich core of the olig-
omer. There is precedence for the unstructured N-terminal
region of PrP affecting the folding and distribution of olig-
omeric species formed by the remainder of the protein. For
example, residues 105–120 are required for the conversion of
-PrP into a soluble -sheet-rich oligomeric species (70).
Indeed, intrinsically disordered domains have been shown to be
involved in protein-protein interactions (78), and there is also
evidence that the interaction of PrPC with -sheet-rich con-
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formers, and the induction of the pro-apoptotic signaling is
dependent on the intrinsically disordered N-terminal region of
PrPC (79).
Given that theN terminus of PrP contains a considerable num-
ber of charged residues (pI PrP91–231 7.95; pI PrP23–231 9.39),
this suggests a principal role for electrostatic interactions in the
formation of the distinct oligomeric state of -PrP23–231. The
highly charged N terminus of the protein may be involved in
directing the formation of distinct oligomeric states that are not
readily accessible to the truncated molecule as residues within
this region transiently contact the folded region of PrP (6, 80,
81). Alternatively, charged surfaces in plasticware or the mem-
brane surfaces used in dialysis may be involved, but of course
this could also happen in vivo where there are a multitude of
charged surfaces available to direct the assembly of discrete
oligomeric species. For example, association of negatively
charged lipids or detergents with PrP are required for its effi-
cient conversion to a -sheet-rich oligomeric form (32, 70). A
role for the involvement of catalytic surfaces directing the for-
mation of distinct assembly states thus remains a distinct
possibility.
In conclusion, we have characterized a novel oligomeric PrP
structure, the formation of which requires the full prion poly-
peptide chain. This highlights that to examine the full reper-
toire of conformers and assembly states that can be accessed by
prion protein under specific experimental conditions ideally
full-length prion protein should be used.
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